Table 5.
Cumulative results of various therapeutic approaches in preemptive therapy and therapy of PTLD adapted from Styczynski et al20
| Therapeutic approach | Cumulative number of treated patients | Cumulative number of patients with cure or improvement | Comments |
|---|---|---|---|
| rituximab in pre-emptive therapy | 341 | 306 (89.7%) | Administration of rituximab was often combined with other therapeutic approaches. |
| rituximab in therapy of PTLD | 146 | 92 (63%) | |
| CTL in pre-emptive therapy | 135 | 127(94.1%) | In most cases reported as a single therapy |
| CTL in therapy of PTLD | 17 | 15 (88.2%) | |
| reduction of immunosuppressive therapy | 76 | 43 (56.6%) | In most cases others therapies were also used |
| Donor lymphocyte infusion | 39 | 16(41.0%) | In most cases others therapies were also used |
| Chemotherapy | 15 | 4(26.7%) | In most cases others therapies were also used |
| Cidofovir in combination with rituximab in pre-emptive therapy | 42 | 37(92.5%) | In all cases others therapies were also used |
| Antiviral agents in therapy of PTLD | 62 | 21(34.4%) |